BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11312688)

  • 1. Metabolism and renal clearance of 111In-labeled DOTA-conjugated antibody fragments.
    Tsai SW; Li L; Williams LE; Anderson AL; Raubitschek AA; Shively JE
    Bioconjug Chem; 2001; 12(2):264-70. PubMed ID: 11312688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments.
    Yazaki PJ; Wu AM; Tsai SW; Williams LE; Ikler DN; Wong JY; Shively JE; Raubitschek AA
    Bioconjug Chem; 2001; 12(2):220-8. PubMed ID: 11312683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody.
    Li L; Olafsen T; Anderson AL; Wu A; Raubitschek AA; Shively JE
    Bioconjug Chem; 2002; 13(5):985-95. PubMed ID: 12236780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of metabolites of 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo.
    Rogers BE; Franano FN; Duncan JR; Edwards WB; Anderson CJ; Connett JM; Welch MJ
    Cancer Res; 1995 Dec; 55(23 Suppl):5714s-5720s. PubMed ID: 7493333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody.
    Li L; Yazaki PJ; Anderson AL; Crow D; Colcher D; Wu AM; Williams LE; Wong JY; Raubitschek A; Shively JE
    Bioconjug Chem; 2006; 17(1):68-76. PubMed ID: 16417253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
    Olafsen T; Kenanova VE; Sundaresan G; Anderson AL; Crow D; Yazaki PJ; Li L; Press MF; Gambhir SS; Williams LE; Wong JY; Raubitschek AA; Shively JE; Wu AM
    Cancer Res; 2005 Jul; 65(13):5907-16. PubMed ID: 15994969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a cathepsin-cleavable peptide linked radioimmunoconjugate of a panadenocarcinoma MAb, m170, in mice and patients.
    DeNardo GL; DeNardo SJ
    Cancer Biother Radiopharm; 2004 Feb; 19(1):85-92. PubMed ID: 15068616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
    Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
    Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.
    Gholipour N; Jalilian AR; Khalaj A; Johari-Daha F; Yavari K; Sabzevari O; Khanchi AR; Akhlaghi M
    Daru; 2014 Jul; 22(1):58. PubMed ID: 25074720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
    Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
    Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates.
    Lewis MR; Raubitschek A; Shively JE
    Bioconjug Chem; 1994; 5(6):565-76. PubMed ID: 7873659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.
    Williams LE; Lewis MR; Bebb GG; Clarke KG; Odom-Maryon TL; Shively JE; Raubitschek AA
    Bioconjug Chem; 1998; 9(1):87-93. PubMed ID: 9460550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.
    Behr TM; Sharkey RM; Sgouros G; Blumenthal RD; Dunn RM; Kolbert K; Griffiths GL; Siegel JA; Becker WS; Goldenberg DM
    Cancer; 1997 Dec; 80(12 Suppl):2591-610. PubMed ID: 9406714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
    Ghosh SC; Pinkston KL; Robinson H; Harvey BR; Wilganowski N; Gore K; Sevick-Muraca EM; Azhdarinia A
    Nucl Med Biol; 2015 Feb; 42(2):177-83. PubMed ID: 25457653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy.
    Kenanova V; Olafsen T; Williams LE; Ruel NH; Longmate J; Yazaki PJ; Shively JE; Colcher D; Raubitschek AA; Wu AM
    Cancer Res; 2007 Jan; 67(2):718-26. PubMed ID: 17234783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to reduce renal radioactivity levels of antibody fragments.
    Arano Y
    Q J Nucl Med; 1998 Dec; 42(4):262-70. PubMed ID: 9973841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA).
    Camera L; Kinuya S; Garmestani K; Brechbiel MW; Wu C; Pai LH; McMurry TJ; Gansow OA; Pastan I; Paik CH
    Eur J Nucl Med; 1994 Jul; 21(7):640-6. PubMed ID: 7957350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of DOTA-conjugated antibody fragments for radioimmunoimaging.
    Smith-Jones PM; Solit DB
    Methods Enzymol; 2004; 386():262-75. PubMed ID: 15120256
    [No Abstract]   [Full Text] [Related]  

  • 19. Renal metabolism of 3'-iodohippuryl N(epsilon)-maleoyl-L-lysine (HML)-conjugated Fab fragments.
    Fujioka Y; Arano Y; Ono M; Uehara T; Ogawa K; Namba S; Saga T; Nakamoto Y; Mukai T; Konishi J; Saji H
    Bioconjug Chem; 2001; 12(2):178-85. PubMed ID: 11312678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro system to estimate renal brush border enzyme-mediated cleavage of Peptide linkages for designing radiolabeled antibody fragments of low renal radioactivity levels.
    Fujioka Y; Satake S; Uehara T; Mukai T; Akizawa H; Ogawa K; Saji H; Endo K; Arano Y
    Bioconjug Chem; 2005; 16(6):1610-6. PubMed ID: 16287261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.